Arcutis Biotherapeutics, Inc. (ARQT) stock
ARQTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/30368% above fair value
$28.26+0.73 (+2.65%)
Close on Nov 13, 2026Market cap $3.55BP/E 128.5Yield –
Arcutis Biotherapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Arcutis Biotherapeutics's profit margin for the twelve months ending Sep 30, 2026 was 5.9%. For fiscal 2025 it was -4.3%, against -71.3% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -4.3% | +67.0 |
| FY2024 | Dec 31, 2024 | -71.3% | +368.5 |
| FY2023 | Dec 31, 2023 | -439.8% | +8010.0 |
| FY2022 | Dec 31, 2022 | -8449.8% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 6.1% | −1.4 |
| Q2 FY2026 | Jun 30, 2026 | 11.6% | +31.0 |
| Q1 FY2026 | Mar 31, 2026 | -10.7% | +27.3 |
| Q4 FY2025 | Dec 31, 2025 | 13.4% | +28.5 |
| Q3 FY2025 | Sep 30, 2025 | 7.5% | +100.3 |
| Q2 FY2025 | Jun 30, 2025 | -19.5% | +150.1 |
| Q1 FY2025 | Mar 31, 2025 | -38.1% | +33.3 |
| Q4 FY2024 | Dec 31, 2024 | -15.1% | +474.9 |
| Q3 FY2024 | Sep 30, 2024 | -92.8% | +24.7 |
| Q2 FY2024 | Jun 30, 2024 | -169.6% | +1198.3 |
| Q1 FY2024 | Mar 31, 2024 | -71.4% | +2808.9 |
| Q4 FY2023 | Dec 31, 2023 | -490.0% | +1942.2 |
| Q3 FY2023 | Sep 30, 2023 | -117.5% | +14738.9 |
| Q2 FY2023 | Jun 30, 2023 | -1367.8% | – |
| Q1 FY2023 | Mar 31, 2023 | -2880.3% | – |
| Q4 FY2022 | Dec 31, 2022 | -2432.3% | – |
| Q3 FY2022 | Sep 30, 2022 | -14856.4% | – |
See a number that looks wrong?